FibroGen, Inc. (0IL8.L) LSE

11.20

+0(+0.00%)

Updated at September 09 03:06PM

Currency In USD

FibroGen, Inc.

Address

409 Illinois Street

San Francisco, CA 94158

United States of America

Phone

415 978 1200

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

225

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Mr. Thane WettigChief Executive Officer & Director1.13M1965
Mr. David DeLuciaChief Financial Officer597,5371989
Ms. Christine L. ChungSenior Vice President of China Operations914,9361968
Mr. John AldenCorporate Secretary & General Counsel0N/A

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.